About Liminal BioSciences
Liminal BioSciences is a company based in Laval (Canada) founded in 1994.. Liminal BioSciences has completed 1 acquisition, including Fairhaven Health. Liminal BioSciences offers products and services including Selective GPR84 Antagonist, Selective OXER1 Antagonist, and GPR40 Agonist Program. Liminal BioSciences operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Laval, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Liminal Biosciences Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$30 M (USD), Post-IPO
Oct 30, 2020
-
Investors
Consonance Capital
& 1 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Liminal BioSciences
Liminal BioSciences offers a comprehensive portfolio of products and services, including Selective GPR84 Antagonist, Selective OXER1 Antagonist, and GPR40 Agonist Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets inflammatory diseases as a GPR84 antagonist in drug development.
Focuses on disease treatment through OXER1 antagonism.
Develops agonists for GPR40 to address metabolic conditions.
Funding Insights of Liminal BioSciences
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(10 Jan 2006)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - Liminal BioSciences | Valuation |
investors |
|
| Jun, 2019 | Amount | Post-IPO - Liminal BioSciences | Valuation |
investors |
|
| Apr, 2019 | Amount | Post-IPO - Liminal BioSciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Liminal BioSciences
Liminal BioSciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Consonance Capital and Thomvest Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments are directed toward fintech, cybersecurity, and martech sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Liminal BioSciences
Liminal BioSciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fairhaven Health. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone pharmacy services are provided in Bellingham, United States.
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Liminal BioSciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Liminal Biosciences Comparisons
Competitors of Liminal BioSciences
Liminal BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Liminal Biosciences
Frequently Asked Questions about Liminal BioSciences
When was Liminal BioSciences founded?
Liminal BioSciences was founded in 1994 and raised its 1st funding round 12 years after it was founded.
Where is Liminal BioSciences located?
Liminal BioSciences is headquartered in Laval, Canada. It is registered at Laval, Quebec, Canada.
What does Liminal BioSciences do?
Founded in 1994 and based in Laval, Canada, operations in the biotechnology sector are focused on the development and commercialization of small molecule drugs targeting respiratory, liver, renal, and rare diseases. Fezagepras is advanced for idiopathic pulmonary fibrosis and Alstrom syndrome treatments, while Ryplazim IV addresses congenital deficiencies and PB-45747 is pursued for nonalcoholic steatohepatitis.
Who are the top competitors of Liminal BioSciences?
Liminal BioSciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Liminal BioSciences offer?
Liminal BioSciences offers Selective GPR84 Antagonist, Selective OXER1 Antagonist, and GPR40 Agonist Program.
How many acquisitions has Liminal BioSciences made?
Liminal BioSciences has made 1 acquisition, including Fairhaven Health.
Who are Liminal BioSciences's investors?
Liminal BioSciences has 2 investors. Key investors include Consonance Capital, and Thomvest Ventures.